This is a research compound, not for human consumption consult a licensed clinician
Your GLP-1 pharma marketing strategy should be omnichannel yet intentional, leveraging the right tools for each stakeholder group
Most recently, we added Efimosfermin Alfa for Nonalcoholic Steatohepatitis, Efimosfermin Alfa for NASH and Tirzepatide + Retatrutide for Fatty Liver Disease to the Power online platform.
Nonetheless, the mechanistic alignment between these pathways provides a biologically plausible rationale for future investigationparticularly in the context of dementia prevention, where upstream metabolic and vascular interventions may offer greater leverage than late-stage amyloid-targeted approaches
Available evidence suggests retatrutide may drive substantial fat-mass reduction, and a recent body-composition substudy reported that the proportion of lean-mass loss relative to total weight loss was similar to other obesity treatments